Herceptin appeal against NICE approval
The UK's National Institute for Health and Clinical Excellence (NICE) has received one appeal against its decision to recommend Swiss drug major Roche's Herceptin (trastuzumab) as adjuvant therapy for early-stage breast cancer. No details of the appellant will be given out by the NICE until the day of a hearing, due on July 26 at a central London venue.
The NICE was praised for its rapid processing of its guidance on Herceptin, which came only two weeks after Roche had received approval from the European Medicines Agency (EMEA; Marketletter June 19) for the drug. This followed a number of highly-publicized law suits by patients demanding access to Herceptin and complaints about the delays in getting guidance from the NICE in a number of high profile cases (Marketletters passim).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze